TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Remote Ischemic Conditioning for Acute Moderate Ischemic Stroke

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patient age ≥18 years;~2. From onset to treatment ≤ 48 hours;~3. Ischemic stroke confirmed by head CT or MRI;~4. 6≤NIHSS score ≤ 16;~5. Premorbid mRS ≤ 1;~6. Signed informed consent.~Exclusion Criteria:~1. Serious neurological deficits before onset ( mRS ≥ 2)；~2. The aetiology of cardiogenic embolism, such as rheumatic mitral or aortic stenosis, artificial heart valve, atrial fibrillation, atrial flutter, sick sinus syndrome, left atrial myxoma, left ventricular wall thrombus or valve neoplasm, congestive heart failure, bacterial endocarditis, etc;~3. Uncontrolled severe hypertension (Systolic pressure ≥180 mmHg or diastolic pressure ≥110 mmHg after drug treatment);~4. Subclavian artery stenosis ≥ 50% or subclavian steal syndrome;~5. Intracranial tumor, arteriovenous malformation or aneurysm;~6. Severe abnormalities in coagulation;~7. Any contraindication for remote ischemic adaptation: the upper limb has serious soft tissue injury, fracture or vascular injury, distal upper limb perivascular lesions, etc.;~8. Comorbidity with any serious diseases and life expectancy is less than half a year;~9. Participating in other clinical trials within 3 months;~10. Patients not suitable for this clinical studies considered by researcher;

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Guideline-based therapy+RIC (Type: EXPERIMENTAL): RIC is given twice a day with 200mmHg pressure.
- Guideline-based therapy (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Rubus Occidentalis Extract on Plasma Glucose Levels in Subject With Prediabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* 19 years of age or older~* prediabetes (fasting plasma glucose 100-125mg/dl, and/or post 75g OGTT plasma glucose 140-199mg/dl)~Exclusion Criteria:~* pregnant women~* taking anti-hyperglycemic agents within 3 months at the time of enrollment~* history of heart failure, myocardial infarction, cerebral infarction~* uncontrolled hypertension (systolic BP \> 160mmHg, or diastolic BP \> 100mmHg)~* serum triglyceride level \> 500mg/dl~* kidney dysfunction (serum Creatinine \> 30% of upper normal limits)~* hepatic dysfunction (AST, ALT \> 3 times of upper normal limits)~* taking systemic glucocorticoids within 1 month

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- control (Type: PLACEBO_COMPARATOR): None
- Rubus occidentalis extract 900mg (Type: ACTIVE_COMPARATOR): taking Rubus occidentalis extract 900mg/day for 12weeks
- Rubus occidentalis extract 1800mg (Type: ACTIVE_COMPARATOR): taking Rubus occidentalis extract 1800mg/day for 12weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Combination of ATRA and High-dose Dexamethasone as First-line Treatment in Adult Immune Thrombocytopenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Confirmed newly-diagnosed, treatment-naive ITP;~2. Platelet counts \<30×109/L ;~3. Platelet counts \< 50×109/L and significant bleeding symptoms (WHO bleeding scale 2 or above);~4. Willing and able to sign written informed consent.~Exclusion Criteria:~1. Received chemotherapy or anticoagulants or other drugs affecting the platelet counts within 6 months before the screening visit;~2. Received first-line and second-line ITP-specific treatments (eg, steriods, cyclophosphamide, 6-mercaptopurine, vincristine, vinblastine, etc) ;~3. Current HIV infection or hepatitis B virus or hepatitis C virus infections;~4. Active infection;~5. Maligancy;~6. Severe medical condition (lung, hepatic or renal disorder) other than chronic ITP. Unstable or uncontrolled disease or condition related to or impacting cardiac function (e.g., unstable angina, congestive heart failure, uncontrolled hypertension or cardiac arrhythmia);~7. Female patients who are nursing or pregnant, who may be pregnant, or who contemplate pregnancy during the study period; a history of clinically significant adverse reactions to previous corticosteroid therapy~8. Have a known diagnosis of other autoimmune diseases, established in the medical history and laboratory findings with positive results for the determination of antinuclear antibodies, anti-cardiolipin antibodies, lupus anticoagulant or direct Coombs test;~9. Patients who are deemed unsuitable for the study by the investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- ATRA and HD-DXM (Type: EXPERIMENTAL): Dexamethasone 40 mg per day, 4 consecutive days (the 4-day course of dexamethasone was repeated in the case of lack of response by day 10) and ATRA 10mg bid po, 12 consecutive weeks
- HD-DXM (Type: ACTIVE_COMPARATOR): Dexamethasone 40 mg per day, 4 consecutive days (the 4-day course of dexamethasone was repeated in the case of lack of response by day 10)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Presyncope (Syncope) Prevention Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. 10 years through 14 years of age~2. The subject must be receiving at least one vaccine delivered intramuscularly~3. The parent/guardian must be willing and capable of providing written informed consent for the adolescent and the adolescent must be willing and capable of providing assent.~4. The subject must be willing to stay for the completion of all study-related activities.~5. Parent/guardian and adolescent must speak and read English by self-report~6. Parent/guardian must be willing to let their child select an electronic game to play during the study~Exclusion Criteria:~1. Receipt of investigational or experimental vaccine or medication within the previous two weeks~2. Receipt of routine injectable medication~3. Permanent indwelling venous catheter~4. Blood drawn within the past hour or scheduled for a blood draw during the post-vaccination observation period~5. Injection of medication during the past hour or scheduled for injection of medication during the observation period.~6. Cold intolerance or cold urticaria~7. Raynaud's phenomenon~8. Sickle cell disease~9. Significant visual impairment or blindness~10. Significant auditory impairment or deafness~11. Febrile (\>38.0°C) or acutely ill individuals~12. Upper arm or shoulder pain or injury~13. Video game-induced seizures~14. Adolescent or parent/Guardian is an immediate relative of study staff or an employee who is supervised by study staff.~15. Any condition that would, in the opinion of the site investigator, place the participant at an unacceptable risk of injury or render the participant unable to meet the requirements of the protocol

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 14 Years
- Healthy Volunteers: t

Study Arms:
- Usual Care (Type: NO_INTERVENTION): Participants received usual care that followed administration of a vaccine and a 20 minute post vaccination observation period.
- Buzzy ® and Electronic Game (Type: EXPERIMENTAL): Buzzy® was applied to the arm receiving vaccination for 30-60 seconds prior to vaccination and removed following vaccination. For the electronic game, participants were instructed to select a game from a prepopulated list of games on a tablet provided by the study team and then played that game for a specified amount of time before, during and after the vaccination administration.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Perineural Local Anesthetic Administration With a Continuous Infusion Versus Automatic Intermittent Boluses

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* patients undergoing painful foot and/or ankle surgery with a planned popliteal sciatic perineural catheter for postoperative analgesia~* age 18 years or older.~Exclusion Criteria:~* Current daily opioid use within the previous 4 weeks~* Clinical neuro-muscular deficit of either the sciatic nerve and its branches and/or innervating muscles~* Morbid obesity \[weight \> 35 kg/m2\]; surgery outside of ipsilateral sciatic and saphenous nerve distributions~* Pregnancy \[as determined by a urine pregnancy test prior to any study interventions\]~* Incarceration.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Continuous Infusion (Type: ACTIVE_COMPARATOR): Patients will receive a continuous infusion of Ropivacaine 0.2% (6 mL/hr, 4 mL patient controlled bolus with 30-minute lockout).
- Automated Boluses (Type: EXPERIMENTAL): Patients will receive intermittent boluses of Ropivacaine 0.2% (8 mL automated bolus every 120 minutes, 4 mL patient controlled bolus with 30-minute lockout).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intermittent Moxifloxacin Therapy For The Prevention Of Acute Exacerbations In Patients With Chronic Bronchitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female out-patients \>/= 45 years~* Subjects suffering from chronic bronchitis~* FEV1\</= 70% and FEV1/FVC \</= 70% predicted from age, height and sex~* No documented episode of AECB (requiring treatment) within 6 weeks of randomization and not experiencing an exacerbation at the time of screening~* Sputum production on most days, even when exacerbation free~* Subjects presented with at least two documented (i.e. requiring antibiotics and/or systemic steroid administration) acute exacerbation episodes during the last 12 monthsIf receiving chronic therapy with inhaled long acting bronchodilators and/or inhaled or systemic steroids, the treatment must have remained stable for the preceding 6 weeks prior to screening~* Smoking history of at least 20 pack-years~* Subjects willing and able to give fully informed written consent~Exclusion Criteria:~* Subjects with contra-indications to moxifloxacin- Known bronchial carcinoma, pulmonary tuberculosis, cystic fibrosis, documented chronic bronchial asthma or diffuse bronchiectasis- Subjects who are actively participating in intensive pulmonary rehabilitation programs~* Subjects with a known history of chronic colonization of pathogenic organisms resistant to moxifloxacin, e.g. Pseudomonas spp, MRSA~* No systemic or inhaled antibiotic therapy during the 6 weeks prior to screening and any long term antibiotic usage~* Subjects requiring home ventilatory support for COPD and those who have a tracheostomy in situ (subjects requiring home/potable oxygen therapy or CPAP for sleep apnea can be included)

- Gender: ALL
- Minimum Age: 45 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): None
- Arm 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of the Effect of 10% Lidocaine Spray Undergoing Coronary Artery Bypass Graft Operation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 50-75 between age patients~* ASA status III patients~* patients undergoing coronary artery bypass graft operation~Exclusion Criteria:~* cardiomyopathy,~* arrhythmia,~* valvular disease,~* electrolyte disorders~* chronic liver and kidney diseases~* use of medication that led to extended QT intervals

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 75 Years
- Healthy Volunteers: t

Study Arms:
- Control group(Group C) (Type: NO_INTERVENTION): After pre-oxygenation, anesthesia induction will be performed with intravenous administration of 2 μg / kg fentanyl, 2 mg/kg propofol, 0.6 mg/kg rocuronium bromide (Esmeron 5 mg vial, Organon Oss Holanda).
- Group L (Type: OTHER): The induction of group L will be performed 5 minutes after administration of 10% topical lidocaine (Lidocaine pump spray 10% 50 ml) 160 mg (16 puffs) application

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dose Finding Study of HP802-247 in Venous Leg Ulcers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~* Provide informed consent.~* Willing to comply with protocol instructions, including allowing all study assessments.~* Have a venous leg ulcer (venous etiology)between the knee and ankle, at or above the malleolus.~* Venous insufficiency confirmed by duplex Doppler ultrasound examination for valvular or venous incompetence.~* Target ulcer duration greater than or equal to 6 weeks but less than or equal to 24 months.~Exclusion Criteria:~* Women who are pregnant or lactating~* Therapy with another investigational agent within thirty (30) days of Screening, or during the study.~* A target ulcer of non-venous etiologies.~* Refusal of or inability to tolerate compression therapy.~* Therapy of the target ulcer with tissue-engineered cell-based skin equivalents within 30 days preceding the Screening Visit.~* Therapy of the target ulcer with topical growth factors within 1 week preceding the Screening Visit.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- A - Low Q7D (Type: EXPERIMENTAL): Low dose HP802-247, applied at each visit
- B - Low Q14D (Type: EXPERIMENTAL): Low dose HP802-247 applied at Visits 1, 3, 5, 7, 9, 11 and Placebo at Visits 2, 4, 6, 8, 10, and 12
- C - High Q7D (Type: EXPERIMENTAL): High dose HP802-247, applied at each visit
- D - High Q14D (Type: EXPERIMENTAL): High dose HP802-247, applied at Visits 1, 3, 5, 7, 9, 11 and Placebo at Visits 2, 4, 6, 8, 10, and 12
- E - Vehicle (Type: PLACEBO_COMPARATOR): Placebo (Vehicle), applied at each visit

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Effectiveness and Safety of Tapentadol (CG5503) in the Treatment of Acute Pain From Bunionectomy.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must undergo primary unilateral first metatarsal bunionectomy~* Pain intensity must be moderate to severe following removal of a continuous popliteal sciatic block~* Female patients must be postmenopausal, surgically sterile, or practicing an effective method of birth control if they are sexually active.~Exclusion Criteria:~* Patients will be excluded from the study if they have a history of seizure disorder or epilepsy~* History of malignancy within the past 2 years before starting the study~* History of alcohol or drug abuse~* Evidence of active infections that may spread to other areas of the body~* Clinical laboratory values reflecting severe renal insufficiency~* Moderately or severely impaired hepatic function~* Currently treated with anticonvulsants, monoamine oxidase inhibitors (MAOIs), tricyclic antidepressants (TCAs), neuroleptics, or serotonin norepinephrine reuptake inhibitor (SNRI).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- 004 (Type: PLACEBO_COMPARATOR): placebo 1 capsule q4-6 hrs for 3 days
- 003 (Type: ACTIVE_COMPARATOR): oxycodone 10mg capsule q4-6 hrs for 3 days
- 001 (Type: EXPERIMENTAL): Tapentadol (CG5503) 50mg capsule q4-6 hrs for 3 days
- 002 (Type: EXPERIMENTAL): Tapentadol (CG5503) 75mg capsule q4-6 hrs for 3 days

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Midazolam Drug Interaction Study With PF-04171327

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy males and/or females (non-childbearing potential) volunteers.~* Cortisol level within normal reference range of the laboratory.~Exclusion Criteria:~* History of intolerance or significant adverse effect with glucocorticoid (steroid) therapy.~* History or current positive results for HIV, Hepatitis B or C or active TB or currently undergoing treatment for TB.~* Known history of hypersensitivity, allergy severe drug reaction or unable to tolerate midazolam or other benzodiazepines.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- PF-04171327 and Midazolam (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Safety and Efficacy of PDP-716

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Be male or female, of 2 years of age or older~2. Have open-angle glaucoma or ocular hypertension in both the eyes~3. Be able and willing to follow study instructions and complete all required visits.~Exclusion Criteria:~1. Females who are pregnant/lactating.~2. Have uncontrolled systemic disease which might interfere with the study~3. Any known allergy or sensitivity to the study medications or their components~4. Any other clinically relevant abnormality

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PDP-716 (Type: EXPERIMENTAL): None
- Brimonidine Tartrate Ophthalmic Solution (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dexamethasone and Respiratory Function After Mastectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* confirmed diagnosis of breast carcinoma~Exclusion Criteria:~* patients with a classification of the American Society of Anesthesiologists classes III and IV.~* pregnancy~* during menstruation~* during steroid therapy~* severe diabetes mellitus (serum HbA1c\> 8%)~* opioids, sedatives or painkillers less than a week before the mastectomy~* history of alcohol or drugs~* patients with a history of inner ear disease and / or severe PONV after any surgical procedure performed in the past

- Gender: FEMALE
- Minimum Age: 20 Years
- Maximum Age: 69 Years
- Healthy Volunteers: f

Study Arms:
- dexamethasone group (Type: ACTIVE_COMPARATOR): patients receive one single dose of intravenous dexamethasone 8 mg.
- placebo group (Type: PLACEBO_COMPARATOR): patients receive one single dose of intravenous placebo.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Exercise Endurance and Lung Hyperinflation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* A diagnosis of stable moderate to severe COPD (GOLD 2006); post-levalbuterol FEV1 \>=30% and \< 80% predicted and FEV1/FVC\<70% predicted~* Current or former cigarette smoker~* Functional Residual Capacity (FRC) measured by body plethysmography \>= 120% of predicted value~* Baseline Dyspnea Index (BDI) focal score ≤ 7 at Visit 4~Exclusion Criteria:~* History of presence of asthma, allergic rhinitis, or atopy~* Hospitalization for acute COPD exacerbation in the 3 months prior to study entry~* Respiratory tract infection (including the upper respiratory tract) or COPD exacerbation in the 6 weeks prior to study entry~* Clinically significant respiratory conditions other than COPD~* Chronic use of oxygen therapy \>= 15 hours a day

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Aclidinium (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete